BIOTECH SHOWCASE: THE INVESTOR CONFERENCE FOR INNOVATORS Ira Spector, CEO of SFA Therapeutics will be presenting a corporate update at the…
Our pipeline includes treatments for Psoriasis, Liver Cancer (Hepatitis B, NASH and HCC), Ophthalmic Diseases, Cytokine Release Syndrome- a side effect in CAR-T, Prevention of Relapse/Recurrence in Leukemias, and other diseases.
Our microbiome-derived drugs are derived from natural substances and enable a new platform to develope treatments which have the potential to treat over 85 chronic inflammatory diseases currently afflicting patients, providing safer treatments than current therapies.
Liver Diseases: Hepatitis B, Steatosis, NASH, NAFLD
Dermatology: Bullous Pemphigus (Rare Autoimmune Disease)
Ophthalmology: Uveitis
Oncology: Liver Cancer, Hepatocellular Carcinoma (HCC), Prevention of Cytokine Storm in CAR T Therapy.
BIOTECH SHOWCASE: THE INVESTOR CONFERENCE FOR INNOVATORS Ira Spector, CEO of SFA Therapeutics will be presenting a corporate update at the…
Abstract Patients who are carriers of the hepatitis B virus (HBV) are at high risk of chronic liver disease (CLD) which…
Funds are focused on Phase 1b clinical trial in psoriasis Read More
